Recently, the US Food and Drug Administration (FDA) released six updated or new forms for companies to use when submitting new tobacco product applications through the Pre-Market Tobacco Product Application (PMTA) and Substantial Equivalence (SE) pathways. Starting from July 6, 2025, applicants must use these new forms to submit PMTA or SE reports. Failure to use the latest version of the forms or to fill them out properly may result in the FDA rejecting the application.
The FDA stated that the updated form took into account public input and is one of the important measures taken by the FDA to improve the efficiency, effectiveness, and transparency of the review process. The new version of the form provides updated instructions for filling out the form and more details, clarifying the information applicants need to provide. This will help applicants submit higher quality applications, thereby speeding up the FDA's review process.
Here is the updated list of tables.
Updated PMTA form:
FDA Form 4057 - Pre-market Tobacco Product Application (PMTA) Submission Form
FDA Form 4057a - Pre-market Application Revision and General Communication Submission Form.
FDA Form 4057b – PMTA New Tobacco Product Unique Identifier Information (formerly known as "Grouping Form")
Updated or new SE form:
FDA Form 3965 - Tobacco Product Substantial Equivalence Report Submission Form.
FDA Form 3965a - Revision of the Substantive Equivalence Report and General Communication Submission Form (formerly FDA Form 3964)
FDA Form 3965b (new) – Unique Identifier Information Form for SE New Tobacco Products
To assist applicants in correctly filling out FDA forms 4057b and 3965b, the FDA has also released the Product Form Validator Tool 2.0. Applicants can use this tool to validate the data in both forms to ensure that the information provided meets FDA's acceptance criteria.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
